Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IRZPG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AB-160
|
|||||
| Synonyms |
AB 160; AB-160; AB160; nab-paclitaxel/bevacizumab complex
Click to Show/Hide
|
|||||
| Organization |
Mayo Clinic
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Bevacizumab
|
Antibody Info | ||||
| Antigen Name |
Vascular endothelial growth factor A (VEGFA)
|
Antigen Info | ||||
| Payload Name |
Paclitaxel
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Cervical cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Melanoma |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Peritoneal cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 1742 | ng/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4333 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Maximum Observed Concentration (Cmax) | 4241 | ng/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4428 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Maximum Observed Concentration (Cmax) | 3266 | ng/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5251 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Maximum Observed Concentration (Cmax) | 5700 | ng/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5260 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Maximum Observed Concentration (Cmax) | 3479 | ng/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5644 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Maximum Observed Concentration (Cmax) | 6160 | ng/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6613 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 4333 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4428 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5251 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5260 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5644 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6613 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 4333 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4428 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5251 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5260 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5644 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6613 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 14.6 | h |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4333 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Clearance (CL) | 29.7 | L/h/m2 |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | 14.7 | h |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 4428 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Clearance (CL) | 29.3 | L/h/m2 |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 125 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | 12.7 | h |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5251 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Clearance (CL) | 31.5 | L/h/m2 |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | 15.5 | h |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5260 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Clearance (CL) | 30.1 | L/h/m2 |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 150 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | 14.3 | h |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 5644 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Clearance (CL) | 32.6 | L/h/m2 |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 1, day 1.
Click to Show/Hide
|
[1] |
| Elimination Half-Life (t1/2) | 16.9 | h |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 6613 | ng*h/mL |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
| Clearance (CL) | 32.6 | L/h/m2 |
Paclitaxel PK properties were characterized for the nine dose-escalation cohort patients following 1-hour and 30-minute intravenous infusions of AB160 on day 1 of Cycle 1 and cycle 2, respectively. 175 mg/m2, Cycle 2, day 1.
Click to Show/Hide
|
[1] |
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Progression Free Survival |
5.3 months
|
|||
| Patients Enrolled |
Eligibility criteria: Adults (≥18) with specific advanced cancers (melanoma/gynecologic) meeting measurable disease requirements, adequate organ function, and prior therapy specifications. Key exclusions: active brain metastases, uncontrolled comorbidities, recent anticancer therapy, pregnancy/nursing, other active malignancies, or significant cardiac/CNS history. Cohort-specific requirements apply for platinum resistance and prior treatments.
Click to Show/Hide
|
||||
| Administration Dosage |
Patients receive nab-paclitaxel/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may receive paclitaxel if supply of nab-paclitaxel is exhausted.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02020707 | Clinical Status | PHASE1 | ||
| Clinical Description | Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) | ||||
| Primary Endpoint |
The primary objectives are to determine the maximum tolerated dose (MTD) within 28 days and assess tumor response (complete/partial per RECIST v1.1) over 12 months in patients with advanced cancers.
|
||||
| Other Endpoint |
Secondary endpoints include progression-free survival (PFS), overall survival (OS) up to 12 months, and comprehensive safety monitoring (CTCAE v4.0-graded AEs) throughout the study period.
|
||||
References